Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc has demonstrated significant growth potential, highlighted by a 41% quarter-over-quarter increase in volumes for its NeXT Personal Dx in Q4'25, surpassing expectations and indicating strong demand for its genomic sequencing services. The company's recent acquisition of Medicare coverage for its proprietary NeXT Personal MRD test, particularly for breast cancer, further solidifies its market position and is expected to enhance volume growth as marketing efforts are ramped up in collaboration with its partner, Tempus. Additionally, the demonstrated efficacy of NeXT Personal in detecting minimal residual disease with a notable performance in early cancer recurrence detection adds to the fundamental strength behind Personalis's growth trajectory.

Bears say

Personalis Inc. faces a negative outlook primarily due to a downward revision of its revenue guidance for 2025, with expected revenue now ranging from $68 million to $73 million, reflecting a year-on-year decline of 12% to 5%. The company has encountered significant challenges, including a slowdown in the biopharma sector and logistical issues with global sample handling, which have negatively impacted its operational performance. Moreover, ongoing substantial losses and existing debt on its balance sheet raise concerns about Personalis's ability to generate sufficient revenue for profitability in the foreseeable future.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.